Kanaph Therapeutics

company

About

Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$21M
Industries
Biotechnology,Life Science,Pharmaceutical
Founded date
Feb 14, 2019
Number Of Employee
11 - 50
Operating Status
Active

Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$27M
Kanaph Therapeutics has raised a total of $27M in funding over 2 rounds. Their latest funding was raised on Oct 12, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 12, 2020 Series B $21M 1 Detail
Oct 22, 2019 Series A $6M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Kanaph Therapeutics is funded by 1 investors. Time Folio Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
Time Folio Asset Management Series B